The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain, J Pharmacol Exp Ther, vol.336, pp.223-256, 2011. ,
188 Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas, Eur J Nucl Med Mol Imaging, vol.35, pp.1838-1884, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00343438
Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model, Int J Pharm, vol.379, pp.317-340, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01230396
Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft, Pharm Res, vol.27, pp.56-64, 2010. ,
Cerebral blood flow changes in glioblastoma patients undergoing bevacizumab treatment are seen in both tumor and normal brain, Neuroradiol J, vol.28, pp.112-121, 2015. ,
The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells, Biomaterials, vol.34, pp.3381-3390, 2013. ,
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation, Proc Natl Acad Sci, vol.110, pp.19059-64, 2013. ,
AZD2171, a panVEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, vol.11, pp.83-95, 2007. ,
Active targeting of brain tumors using nanocarriers, Biomaterials, vol.28, pp.4947-67, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00198695
Nucleoside-lipid-based nanocarriers for sorafenib delivery, Nanoscale Res Lett, vol.13, p.17, 2018. ,
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells, Int J Pharm, vol.493, pp.75-85, 2015. ,
Tumor angiogenesis and interstitial hypertension, Cancer Res, vol.56, pp.4264-4270, 1996. ,
Management of sorafenib-related adverse events: a clinician's perspective, Semin Oncol, vol.41, pp.1-16, 2014. ,
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures, Cell Cycle Georget. Tex, vol.12, pp.491-500, 2013. ,
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies, Annu Rev Chem Biomol Eng, vol.2, pp.281-98, 2011. ,
Targeted therapeutics in patients with high-grade gliomas: past, present, and future, Curr Treat Options Oncol, vol.17, p.42, 2016. ,
Characterization of the distribution, retention, and efficacy of internal radiation of 188 Re-lipid nanocapsules in an immunocompromised human glioblastoma model, J Neurooncol, vol.131, pp.49-58, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01451658
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?, J Exp Clin Cancer Res CR, vol.36, p.135, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01631360
Galactosylated polymeric carriers for liver targeting of sorafenib, Int J Pharm, vol.466, pp.172-80, 2014. ,
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation, Int J Pharm, vol.481, pp.154-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01392431
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas, Int J Radiat Oncol Biol Phys, vol.85, pp.321-329, 2013. ,
Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab, JCO, vol.29, pp.308-319, 2011. ,
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer, Biomaterials, vol.67, pp.194-203, 2015. ,
Active targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles, Adv Healthc Mater, vol.4, pp.1681-90, 2015. ,
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study, Anticancer Drugs, vol.25, pp.723-731, 2014. ,
A novel phase inversionbased process for the preparation of lipid nanocarriers, Pharm Res, vol.19, pp.875-80, 2002. ,
Tumour targeting of lipid nanocapsules grafted with cRGD peptides, Eur J Pharm Biopharm, vol.87, pp.152-161, 2014. ,
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma, Br J Cancer, vol.110, pp.2655-61, 2014. ,
The adaptation of lipid nanocapsule formulations for blood administration in animals, Int J Pharm, vol.379, pp.266-275, 2009. ,
Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice, Pharm Res, vol.27, pp.421-451, 2010. ,
Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect, Pharm Res, vol.28, pp.3189-98, 2011. ,
Administrationdependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma, Int J Pharm, vol.423, pp.55-62, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01865009
Lipid nanocapsules: a new platform for nanomedicine, Int J Pharm, vol.379, pp.201-210, 2009. ,
Correlation of tumor size and metabolism with perfusion in hepatocellular carcinoma using dynamic contrast enhanced CT and F-18 FDG PET-CT, J Nucl Med, vol.56, p.1330, 2015. ,
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, vol.307, pp.58-62, 2005. ,
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy, Nat Med, vol.7, pp.987-989, 2001. ,
Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts, Cancer Res, vol.49, pp.3759-3764, 1989. ,
Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art, J Control Release, vol.227, pp.23-37, 2016. ,
High-resolution myocardial perfusion mapping in small animals in vivo by spin-labeling gradientecho imaging, Magn Reson Med, vol.51, pp.62-67, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-02119122
Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules, Nanomedicine Nanotechnol Biol Med, vol.10, pp.1667-1677, 2014. ,
Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules, Eur J Pharm Biopharm, vol.81, pp.690-693, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01877954
Cytotoxicity and genotoxicity of lipid nanocapsules, Toxicol in Vitro, vol.41, pp.189-199, 2017. ,
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02, NeuroOncol, vol.14, pp.1511-1518, 2012. ,
Perfluorocarbon-loaded lipid nanocapsules to assess the dependence of U87-human glioblastoma tumor pO 2 on in vitro expansion conditions, PloS One, vol.11, p.165479, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01393746
Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics, Int J Pharm, vol.489, pp.83-90, 2015. ,
Recent advances in targeted therapy for glioma, Curr Med Chem, vol.24, pp.1365-1381, 2017. ,
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis, J Control Release, vol.221, pp.62-70, 2016. ,
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma, J Pharm Sci, vol.104, pp.1187-1196, 2015. ,
In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid)-cystamine hydrochloride-D-a-tocopherol succinate, J Biomater Sci Polym Ed, vol.27, pp.1729-1747, 2016. ,
Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma, Int J Pharm, vol.495, pp.972-980, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01392247
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models, J Pharmacol Exp Ther, vol.305, pp.833-839, 2003. ,
Emerging targeted therapies for glioma, Expert Opin Emerg Drugs, vol.21, pp.441-452, 2016. ,
PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure, Nanomedicine Nanotechnol Biol Med, vol.14, pp.557-567, 2018. ,
Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2, PloS One, vol.8, p.58262, 2013. ,
Advances in neurotherapeutic delivery technologies, OMICS International, 2015. ,
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme, Neuro-oncology, vol.15, pp.490-496, 2013. ,
Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI, Cancer Med, vol.3, pp.47-60, 2014. ,
Effect of CYP3Ainducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma, J Neurooncol, vol.101, pp.57-66, 2011. ,
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration, Eur J Pharm Biopharm, vol.79, pp.181-188, 2011. ,
The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy, Biomaterials, vol.32, pp.2106-2116, 2011. ,
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide, Eur J Pharm Sci, vol.50, pp.172-180, 2013. ,
Locoregional confinement and major clinical benefit of 188 Re-Loaded CXCR4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma, Theranostics, vol.7, pp.4517-4536, 2017. ,
Sorafenib exerts antiglioma activity in vitro and in vivo, Neurosci Lett, vol.478, pp.165-170, 2010. ,
Imaging blood flow in brain tumors using arterial spin labeling, Magn Reson Med, vol.44, pp.169-173, 2000. ,
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion, Cancer Res, vol.72, pp.402-407, 2012. ,
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.459-466, 2009. ,
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-996, 2005. ,
Perfusion MRI of U87 brain tumors in a mouse model, Magn Reson Med, vol.51, pp.893-899, 2004. ,
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model, BMC Cancer, vol.15, p.522, 2015. ,
Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)re-lipid nanocapsules, Biomaterials, vol.32, pp.6781-6790, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00638699
In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy, J Neurooncol, vol.97, pp.195-205, 2010. ,
Effects of convectionenhanced delivery of bevacizumab on survival of glioma-bearing animals, Neurosurg Focus, vol.38, p.8, 2015. ,
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat Rev Drug Discov, vol.5, pp.835-844, 2006. ,
Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment, Colloids Surf B Biointerfaces, vol.141, pp.83-92, 2016. ,
DOI : 10.1016/j.colsurfb.2016.01.016
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3, Mol Cancer Ther, vol.9, pp.953-962, 2010. ,
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer, Int J Nanomedicine, vol.11, pp.2329-2343, 2016. ,
Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers, Carbohydr Polym, vol.136, pp.782-790, 2016. ,
Antiangiogenic effect of bevacizumab: Application of arterial spin-labeling perfusion MR imaging in a rat glioblastoma model, AJNR Am J Neuroradiol, vol.37, pp.1650-1656, 2016. ,
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy, 2016. ,
, Nanomedicine Nanotechnol Biol Me, vol.12, pp.1303-1311
Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy, Nanomed, vol.12, pp.911-925, 2017. ,
Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro, Int J Nanomedicine, vol.8, pp.1517-1524, 2013. ,
The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer, Biomaterials, vol.35, pp.4565-4572, 2014. ,
AG488 as a therapy against gliomas, Oncotarget, vol.8, pp.71833-71844, 2017. ,
DOI : 10.18632/oncotarget.18284
URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=18284&path%5B%5D=58630
Sorafenib plus daily lowdose temozolomide for relapsed glioblastoma: a phase II study, Anticancer Res, vol.33, pp.3487-3494, 2013. ,